Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study
Identifieur interne : 001108 ( France/Analysis ); précédent : 001107; suivant : 001109Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study
Auteurs : P. Carrière [France] ; D. Bonhomme [France] ; T. Lempérière [France]Source :
- European Psychiatry [ 0924-9338 ] ; 2000.
English descriptors
Abstract
In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10–30 mg/d) or amisulpride (400–1200 mg/d) for four months. More patients in the haloperidol group withdrew prematurely (44% vs 26%; P = 0.0077) due to a higher incidence of adverse events. Amisulpride was at least as effective as haloperidol in reducing the Brief Psychiatric Rating Scale (BPRS) total score (–27.3 vs –21.9) (non-inferiority test; P < 0.001). The PANSS positive score improved to a similar extent in both groups whilst improvement in the PANSS negative score was significantly greater with amisulpride (–10.5 vs –7.2; P = 0.01). The percentage of responders on the Clinical Global Impression scale was also significantly greater with amisulpride (71% vs 47%; P < 0.001). Both the Quality of Life Scale (QLS) and the Functional Status Questionnaire (FSQ) improved to a significantly greater extent under amisulpride. Haloperidol was associated with a greater incidence in extrapyramidal symptoms and with a greater increase in the Simpson-Angus score than was seen with amisulpride (0.32 vs 0.02; P < 0.001). In conclusion, amisulpride is globally superior to haloperidol in the treatment of acute exacerbations of schizophrenia and significantly improves patients’ quality of life and social adjustment.
Url:
DOI: 10.1016/S0924-9338(00)00401-6
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001357
- to stream Istex, to step Curation: 001357
- to stream Istex, to step Checkpoint: 000A15
- to stream Main, to step Merge: 001A24
- to stream Main, to step Curation: 001977
- to stream Main, to step Exploration: 001977
- to stream France, to step Extraction: 001108
Links to Exploration step
ISTEX:3AC3DD9FAEFC48DA2C3CCA2E05464B2D6B3B7A4DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study</title><author><name sortKey="Carriere, P" sort="Carriere, P" uniqKey="Carriere P" first="P" last="Carrière">P. Carrière</name></author><author><name sortKey="Bonhomme, D" sort="Bonhomme, D" uniqKey="Bonhomme D" first="D" last="Bonhomme">D. Bonhomme</name></author><author><name sortKey="Lemperiere, T" sort="Lemperiere, T" uniqKey="Lemperiere T" first="T" last="Lempérière">T. Lempérière</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3AC3DD9FAEFC48DA2C3CCA2E05464B2D6B3B7A4D</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0924-9338(00)00401-6</idno><idno type="url">https://api.istex.fr/document/3AC3DD9FAEFC48DA2C3CCA2E05464B2D6B3B7A4D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001357</idno><idno type="wicri:Area/Istex/Curation">001357</idno><idno type="wicri:Area/Istex/Checkpoint">000A15</idno><idno type="wicri:doubleKey">0924-9338:2000:Carriere P:amisulpride:has:a</idno><idno type="wicri:Area/Main/Merge">001A24</idno><idno type="wicri:Area/Main/Curation">001977</idno><idno type="wicri:Area/Main/Exploration">001977</idno><idno type="wicri:Area/France/Extraction">001108</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study</title><author><name sortKey="Carriere, P" sort="Carriere, P" uniqKey="Carriere P" first="P" last="Carrière">P. Carrière</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service Médico-Psychologique Régional, BP 549, 36021 Châteauroux</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region><settlement type="city">Châteauroux</settlement></placeName></affiliation></author><author><name sortKey="Bonhomme, D" sort="Bonhomme, D" uniqKey="Bonhomme D" first="D" last="Bonhomme">D. Bonhomme</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Sanofi Synthélabo-France, 22, avenue Galilée, 92352 le Plessis Robinson</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">le Plessis Robinson</settlement></placeName></affiliation></author><author><name sortKey="Lemperiere, T" sort="Lemperiere, T" uniqKey="Lemperiere T" first="T" last="Lempérière">T. Lempérière</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>28 rue des Acacias, 75017 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Psychiatry</title><title level="j" type="abbrev">EURPSY</title><idno type="ISSN">0924-9338</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="329">329</biblScope></imprint><idno type="ISSN">0924-9338</idno></series><idno type="istex">3AC3DD9FAEFC48DA2C3CCA2E05464B2D6B3B7A4D</idno><idno type="DOI">10.1016/S0924-9338(00)00401-6</idno><idno type="PII">S0924-9338(00)00401-6</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0924-9338</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>amisulpride</term><term>antipsychotic</term><term>atypical antipsychotic</term><term>haloperidol</term><term>schizophrenia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10–30 mg/d) or amisulpride (400–1200 mg/d) for four months. More patients in the haloperidol group withdrew prematurely (44% vs 26%; P = 0.0077) due to a higher incidence of adverse events. Amisulpride was at least as effective as haloperidol in reducing the Brief Psychiatric Rating Scale (BPRS) total score (–27.3 vs –21.9) (non-inferiority test; P < 0.001). The PANSS positive score improved to a similar extent in both groups whilst improvement in the PANSS negative score was significantly greater with amisulpride (–10.5 vs –7.2; P = 0.01). The percentage of responders on the Clinical Global Impression scale was also significantly greater with amisulpride (71% vs 47%; P < 0.001). Both the Quality of Life Scale (QLS) and the Functional Status Questionnaire (FSQ) improved to a significantly greater extent under amisulpride. Haloperidol was associated with a greater incidence in extrapyramidal symptoms and with a greater increase in the Simpson-Angus score than was seen with amisulpride (0.32 vs 0.02; P < 0.001). In conclusion, amisulpride is globally superior to haloperidol in the treatment of acute exacerbations of schizophrenia and significantly improves patients’ quality of life and social adjustment.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Centre-Val de Loire</li><li>Région Centre</li><li>Île-de-France</li></region><settlement><li>Châteauroux</li><li>Paris</li><li>le Plessis Robinson</li></settlement></list><tree><country name="France"><region name="Centre-Val de Loire"><name sortKey="Carriere, P" sort="Carriere, P" uniqKey="Carriere P" first="P" last="Carrière">P. Carrière</name></region><name sortKey="Bonhomme, D" sort="Bonhomme, D" uniqKey="Bonhomme D" first="D" last="Bonhomme">D. Bonhomme</name><name sortKey="Lemperiere, T" sort="Lemperiere, T" uniqKey="Lemperiere T" first="T" last="Lempérière">T. Lempérière</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001108 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 001108 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:3AC3DD9FAEFC48DA2C3CCA2E05464B2D6B3B7A4D
|texte= Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study
}}
| This area was generated with Dilib version V0.6.25. |  |